Transcript or could treat sepsis and infections caused by

What if Nature had already designed drugs…
that could induce remission of rheumatoid arthritis?
…..or could treat sepsis and infections caused
by multi-drug resistant bacteria?
Orynotides™
Discovery, Design and Clinical Development
of Retroevolutionary Peptide Therapeutics
Why are Old World monkeys so highly resistant
to sepsis and other inflammatory diseases?
Discovery of pleotropic cyclic peptides (theta defensins) in
Old World primates, not in apes or humans
Exploiting a retroevolutionary strategy, Orynotides™,
derived from theta defensins from Old World monkeys are:
• New class of agents for treatment of infection and
autoimmune/inflammatory diseases
• Highly active microbicides against multi-drug resistant
bacteria and fungi
• Efficacious in rodent models of severe sepsis
• Rapidly arrest and induce remission in rodent models of
rheumatoid arthritis
• Readily manufacturable, stable, safe, nonimmunogenic, non-immunocompromising
18 aa cyclic peptide
Hmmm, maybe
I have what
you need…
Orynotides™: Engineered Theta-Defensins
Microbicidal against MDR Bacteria and “Superbugs”
Mice infected with
carbapenem-resistant
Klebsiella pneumoniae
and treated with saline
or OTP-602
Orynotides™ do not
select for bacterial
or fungal resistance
Orynotides™ are highly effective in rodent models of sepsis
4h tx
24h tx
* P <0.05; ** P < 0.001
48 h post surgical sepsis,
Saline treatment only, 4 h
post surgery
48 h post surgical sepsis,
Single i.v. Orynotide™
treatment 4 h post surgery
Single Orynotide™ treatments
are effective 4 or 24 h after
sepsis induction
MOA is modulation of the sepsis-induced cytokine
storm plus induction of bacterial clearance
The MOA of Orynotides™ Predicts Efficacy in Rheumatoid
Arthritis and Related Autoimmune/Inflammatory Diseases
Contact us for a link to watch this video.
Pristane (mineral oil) induced arthritis in rats: a robust surrogate for human RA
Comparison of Orynotide™ ORTD-1 to first line RA drugs
ORTD-1 (n = 16)
Only ORTD-1 induces remission of disease
ORTD-1: First-in- class Therapeutic for RA
• Oryn awarded first and only SBIR Direct Phase 2 Award by NIAMS (NIH)
• ORTD-1 highly effective in two preclinical models of RA
• Non-toxic: at least 50-fold safety ratio by all routes of administration
• Long circulating half-life: effective with q 5 day s.c. dosing in rat RA
• Exceedingly stable – no degradation in rat plasma for six weeks
• Non-immunocompromising
• Readily produced at scale by chemical synthesis (0.5 kg GLP ORTD-1 in hand)
• Non-immunogenic- no neutralizing antibodies in animals challenged daily for
six weeks
• Oryn’s products and technologies are protected by seven issued US Patents
and corresponding foreign filings
Engineered Orynotides™ for MDR Infections
• $5.3 M NIH award to develop Orynotides™ as novel agents to treat superbug
infections
• Orynotides™ effective in animal models of bacterial and polymicrobial sepsis
• Engineered Orynotides™ are therapeutic in rodent models of carbapenem
resistant bacterial infections
• Orynotides™ are fungicidal against MDR fungal pathogens
• Highly stable and non-toxic
• No selection for Orynotide™ resistance following up to 20 passages in MIC 90
peptide concentrations
• Orally bioavailable
Orynotides™
Revolutionary drugs designed by employing
retroevolutionary concepts of immunobiology